Yarrow Bioscience Total Assets Growth & History (YARW)
Yarrow Bioscience's total assets was $30.2M for fiscal 2025.
View full Yarrow Bioscience company overviewYarrow Bioscience annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $30.2M | −$36.7M | −54.92% |
| 2024 | 2024-12-31 | $66.9M | −$30.8M | −31.51% |
| 2023 | 2023-12-31 | $97.7M | $56.9M | +139.67% |
| 2022 | 2022-12-31 | $40.8M | −$26.3M | −39.21% |
| 2021 | 2021-12-31 | $67.0M | −$26.7M | −28.48% |
| 2020 | 2020-12-31 | $93.7M | $12.6M | +15.50% |
| 2019 | 2019-12-31 | $81.2M | −$58.8M | −42.00% |
| 2018 | 2018-12-31 | $139.9M | $73.1M | +109.26% |
| 2017 | 2017-12-31 | $66.9M | $24.8M | +59.01% |
| 2016 | 2016-12-31 | $42.1M | — | — |
Yarrow Bioscience quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $23.6M | −$21.1M | −47.22% |
| Q1 2026 | 2026-03-31 | $25.9M | −$30.6M | −54.14% |
| Q4 2025 | 2025-12-31 | $30.2M | −$36.7M | −54.92% |
| Q2 2025 | 2025-06-30 | $44.7M | −$41.9M | −48.39% |
| Q1 2025 | 2025-03-31 | $56.4M | −$35.3M | −38.45% |
| Q4 2024 | 2024-12-31 | $66.9M | −$30.8M | −31.51% |
| Q3 2024 | 2024-09-30 | $76.2M | $56.9M | +295.48% |
| Q2 2024 | 2024-06-30 | $86.6M | $61.7M | +247.16% |
| Q1 2024 | 2024-03-31 | $91.7M | $56.4M | +159.98% |
| Q4 2023 | 2023-12-31 | $97.7M | $56.9M | +139.67% |
| Q3 2023 | 2023-09-30 | $19.3M | −$27.6M | −58.93% |
| Q2 2023 | 2023-06-30 | $25.0M | −$30.2M | −54.78% |
| Q1 2023 | 2023-03-31 | $35.3M | −$29.1M | −45.17% |
| Q4 2022 | 2022-12-31 | $40.8M | −$26.3M | −39.21% |
| Q3 2022 | 2022-09-30 | $46.9M | −$34.4M | −42.31% |
| Q2 2022 | 2022-06-30 | $55.2M | −$78.8M | −58.81% |
| Q1 2022 | 2022-03-31 | $64.3M | −$84.9M | −56.88% |
| Q4 2021 | 2021-12-31 | $67.0M | −$26.7M | −28.48% |
| Q3 2021 | 2021-09-30 | $81.3M | −$26.4M | −24.49% |
| Q2 2021 | 2021-06-30 | $134.0M | $3.1M | +2.40% |
| Q1 2021 | 2021-03-31 | $149.2M | −$11.4M | −7.08% |
| Q4 2020 | 2020-12-31 | $93.7M | $12.6M | +15.50% |
| Q3 2020 | 2020-09-30 | $107.7M | $11.1M | +11.50% |
| Q2 2020 | 2020-06-30 | $130.8M | $16.5M | +14.39% |
| Q1 2020 | 2020-03-31 | $160.5M | $34.3M | +27.15% |
| Q4 2019 | 2019-12-31 | $81.2M | −$58.8M | −42.00% |
| Q3 2019 | 2019-09-30 | $96.6M | −$58.4M | −37.68% |
| Q2 2019 | 2019-06-30 | $114.4M | −$52.5M | −31.47% |
| Q1 2019 | 2019-03-31 | $126.3M | −$54.2M | −30.04% |
| Q4 2018 | 2018-12-31 | $139.9M | $73.1M | +109.26% |
| Q3 2018 | 2018-09-30 | $155.0M | — | — |
| Q2 2018 | 2018-06-30 | $166.9M | — | — |
| Q1 2018 | 2018-03-31 | $180.5M | — | — |
| Q4 2017 | 2017-12-31 | $66.9M | $24.8M | +59.01% |
| Q4 2016 | 2016-12-31 | $42.1M | — | — |
Yarrow Bioscience total assets trends
Over the last five fiscal years, Yarrow Bioscience's total assets decreased from $93.7M to $30.2M, a change of −$63.6M. The latest reported quarter, Q2 2026, shows $23.6M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Yarrow Bioscience source filings ↗